NCT01453296View on ClinicalTrials.gov

Pharmacokinetics and Pharacodynamics of GW642444 in Paedetric Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions
Asthma
Interventions
DRUG

GW642444

GW642444 25 μg; Novel dry powder inhaler

DRUG

Placebo

Matching placebo; Novel dry powder inhaler

Trial Locations (5)

61761

GSK Investigational Site, Normal

80206

GSK Investigational Site, Denver

90630

GSK Investigational Site, Cypress

92647

GSK Investigational Site, Huntington Beach

97504

GSK Investigational Site, Medford

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01453296 - Pharmacokinetics and Pharacodynamics of GW642444 in Paedetric Subjects | Biotech Hunter | Biotech Hunter